Development of thioquinazolinones, allosteric Chk1 kinase inhibitors.

A high throughput screening campaign was designed to identify allosteric inhibitors of Chk1 kinase by testing compounds at high concentration. Activity was then observed at K(m) for ATP and at near-physiological concentrations of ATP. This strategy led to the discovery of a non-ATP competitive thioquinazolinone series which was optimized for potency and stability. An X-ray crystal structure for the complex of our best inhibitor bound to Chk1 was solved, indicating that it binds to an allosteric site approximately 13A from the ATP binding site. Preliminary data is presented for several of these compounds.

[1]  L. Johnson,et al.  Two structures of the catalytic domain of phosphorylase kinase: an active protein kinase complexed with substrate analogue and product. , 1995, Structure.

[2]  A. Cuddihy,et al.  Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells , 2001, Oncogene.

[3]  Jean M. Severin,et al.  Abrogation of G2 checkpoint specifically sensitize p53 defective cells to cancer chemotherapeutic agents. , 2001, Anticancer research.

[4]  J. Woodgett.  Protein kinase functions , 2000 .

[5]  D. Parry,et al.  Chk1 is Essential for Tumor Cell Viability Following Activation of the Replication Checkpoint , 2005, Cell cycle.

[6]  T. Ishida,et al.  Human DNA damage checkpoints and their relevance to soft tissue sarcoma , 2004, Pathology international.

[7]  Jiri Bartek,et al.  Chk1 and Chk2 kinases in checkpoint control and cancer. , 2003, Cancer cell.

[8]  P. Ram,et al.  The Synthesis of Some S-Substituted-2-mercapto-3-aryl-4-quinazolones , 1965 .

[9]  O. Seitz,et al.  Cover Picture: Forced Intercalation Probes (FIT Probes): Thiazole Orange as a Fluorescent Base in Peptide Nucleic Acids for Homogeneous Single-Nucleotide-Polymorphism Detection (ChemBioChem 1/2005) , 2005 .

[10]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[11]  T. Kawabe.  G2 checkpoint abrogators as anticancer drugs. , 2004, Molecular cancer therapeutics.

[12]  M. Prudhomme.  Novel checkpoint 1 inhibitors. , 2006, Recent patents on anti-cancer drug discovery.

[13]  Nader Fotouhi,et al.  Cell cycle inhibitors for the treatment of cancer , 2003 .

[14]  Michael Reilly,et al.  Development of 6-substituted indolylquinolinones as potent Chek1 kinase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[15]  Hilmar Weinmann,et al.  Editorial: Drug Discovery Process for Kinease Inhibitors , 2005 .

[16]  G. Enders,et al.  Cdk inhibition in human cells compromises chk1 function and activates a DNA damage response. , 2005, Cancer research.

[17]  Zhan Xiao,et al.  Selective Chk1 inhibitors differentially sensitize p53‐deficient cancer cells to cancer therapeutics , 2006, International journal of cancer.

[18]  J. D. de Bono,et al.  Drugging cell cycle kinases in cancer therapy. , 2005, Current drug targets.

[19]  Jiri Bartek,et al.  Targeting the checkpoint kinases: chemosensitization versus chemoprotection , 2004, Nature Reviews Cancer.

[20]  Hilmar Weinmann Dr. and,et al.  Editorial: Drug Discovery Process for Kinease Inhibitors , 2005 .

[21]  Lawrence C Kuo,et al.  3-(Indol-2-yl)indazoles as Chek1 kinase inhibitors: Optimization of potency and selectivity via substitution at C6. , 2006, Bioorganic & medicinal chemistry letters.